Evidence map›Paper›PMID 34178711›Full record

ArticleEuropean thyroid journal2021

Long-Term Outcomes of Tamoxifen Citrate Therapy and Histo- and Immunopathological Properties in Riedel Thyroiditis.

Asena Gökçay Canpolat, Murat Cinel, Serpil Dizbay Sak, Işılay Taşkaldıran, Hakan Korkmaz, Özgür Demir, Reyhan Ersoy, Selçuk Dağdelen, Dilek Berker, Klara Dalva and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European thyroid journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Asena Gökçay CanpolatDepartment of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
Murat CinelDepartment of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
Serpil Dizbay SakDepartment of Pathology, School of Medicine, Ankara University, Ankara, Turkey.
Işılay TaşkaldıranDepartment of Endocrinology and Metabolism, Ankara Training and Research Hospital, Ankara, Turkey.
Hakan KorkmazDepartment of Endocrinology and Metabolism, School of Medicine, Süleyman Demirel University, Isparta, Turkey.
Özgür DemirDepartment of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
Reyhan ErsoyDepartment of Endocrinology and Metabolism, School of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Selçuk DağdelenDepartment of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey.
Dilek BerkerDepartment of Endocrinology and Metabolism, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Klara DalvaDepartment of Haematology, School of Medicine, Ankara University, Ankara, Turkey.
Adile Begüm Bahçecioğlu MutluDepartment of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
Murat Faik ErdoğanDepartment of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
Ankara University · TRAnkara Yıldırım Beyazıt University · TRHacettepe University · TRMinistry of Health · TRSağlık Bilimleri Üniversitesi · TRSüleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRiedel thyroiditis (RT) is a rare form of thyroiditis; thus, data about the disease course and treatment options are limited. Therefore, we aimed to assess the clinical, serological, radiological, and histopathological features, as well as short- and long-term follow-up of RT patients under glucocorticoid (GC) and tamoxifen citrate (TMX). Parameters related to IgG4-related diseases (IgG4-RD) were also investigated.

methodsEight patients with RT diagnosed between 2000 and 2019 were enrolled. Data were collected in a retrospective and prospective manner. The diagnosis was confirmed with histopathological features in all patients. Results of the treatment with GCs on short- to mid-term, followed by TMX in the long term, were evaluated.

resultsThe mean age at diagnosis was 40.5 ± 6.8 years; female predominance was observed (F/M:7/1). Parameters related to IgG4-RD, like increase in IgG4 serum levels, total plasmablast counts, and IgG4+ plasmablasts, were negative in most of our patients in both active and inactive states of the disease. Likewise, an increased ratio of IgG4/IgG-positive plasma cells >40% could only be observed in 2 cases. GCs followed by TMX were given to the patients with an over-all median follow-up time of 67 (8-216) months. All the patients considerably improved clinically and had a reduction in the size of the mass lesion on GCs, followed by TMX therapy. None of the patients had a recurrence under TMX therapy for a median period of 18.5 (7-96) months.

conclusionEven though RT is suggested to be a member of IgG4-RD, serologic or histological evidence of IgG4 elevation or positivity is only useful for diagnosis and follow-up of RT. The diagnosis should be based on clinical and radiological evidence and confirmed by histopathology. GCs are effective for initial treatment, and TMX is a successful and safe therapeutic option for long-term maintenance therapy.

Indexed as

Immunoglobulin G4-related diseaseIntercellular adhesion molecule-1PlasmablastRiedel thyroiditisTamoxifen citrateTransforming growth factor beta

Identifiers

PMID34178711
PMCPMC8216025
OpenAlexW3110767511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.